Literature DB >> 33718974

The Kobe University Human Intestinal Microbiota Model for gut intervention studies.

Namiko Hoshi1, Jun Inoue1, Daisuke Sasaki2, Kengo Sasaki3,4.   

Abstract

The human gut harbors a complex microbial community that performs a range of metabolic, physiological, and immunological functions. The host and its inhabiting microorganisms are often referred to as a "superorganism." Dysbiosis of gut microflora has been associated with the pathogenesis of intestinal disorders including inflammatory bowel disease, colorectal cancer, and extra-intestinal disorders such as cardiovascular disease. Therefore, gut microbiome interventions are important for the prevention and treatment of diseases. However, ethical, economic, scientific, and time constraints limit the outcome of human intervention or animal studies targeting gut microbiota. We recently developed an in vitro batch fermentation model (the Kobe University Human Intestinal Microbiota Model, KUHIMM) that is capable of hosting a majority of gut microbial species in humans and also detects the metabolites produced by microorganisms in real time. In this mini review, we elucidated the characteristics of the KUHIMM and its applicability in analyzing the effect of diet, drugs, probiotics, and prebiotics on intestinal bacteria. In addition, we introduce as examples its application to disease models, such as ulcerative colitis, in which intestinal bacteria are intricately involved in the process of pathogenesis. We also discuss the potential of the KUHIMM in precision medicine. KEY POINTS: • In vitro gut fermentation model to simulate human colonic microbiota • Screening of potential prebiotics and probiotic candidates in healthy model • Construction of disease models of ulcerative colitis and coronary artery disease.

Entities:  

Keywords:  Coronary artery disease; Gut; In vitro model; Microbiota; Ulcerative colitis

Mesh:

Substances:

Year:  2021        PMID: 33718974     DOI: 10.1007/s00253-021-11217-x

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  47 in total

1.  Ethical Criteria for Human Challenge Studies in Infectious Diseases.

Authors:  Ben Bambery; Michael Selgelid; Charles Weijer; Julian Savulescu; Andrew J Pollard
Journal:  Public Health Ethics       Date:  2015-09-27       Impact factor: 1.940

2.  Hot topics in gut microbiota.

Authors:  Joël Doré; Magnus Simrén; Lisa Buttle; Francisco Guarner
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

Review 3.  Intraluminal pH of the human gastrointestinal tract.

Authors:  J Fallingborg
Journal:  Dan Med Bull       Date:  1999-06

4.  Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL).

Authors:  Andre Franke; Tobias Balschun; Christian Sina; David Ellinghaus; Robert Häsler; Gabriele Mayr; Mario Albrecht; Michael Wittig; Eva Buchert; Susanna Nikolaus; Christian Gieger; H Erich Wichmann; Jurgita Sventoraityte; Limas Kupcinskas; Clive M Onnie; Maria Gazouli; Nicholas P Anagnou; David Strachan; Wendy L McArdle; Christopher G Mathew; Paul Rutgeerts; Séverine Vermeire; Morten H Vatn; Michael Krawczak; Philip Rosenstiel; Tom H Karlsen; Stefan Schreiber
Journal:  Nat Genet       Date:  2010-03-14       Impact factor: 38.330

5.  Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial.

Authors:  Samuel P Costello; Patrick A Hughes; Oliver Waters; Robert V Bryant; Andrew D Vincent; Paul Blatchford; Rosa Katsikeros; Jesica Makanyanga; Melissa A Campaniello; Chris Mavrangelos; Carly P Rosewarne; Chelsea Bickley; Cian Peters; Mark N Schoeman; Michael A Conlon; Ian C Roberts-Thomson; Jane M Andrews
Journal:  JAMA       Date:  2019-01-15       Impact factor: 56.272

6.  Short chain fatty acids in human large intestine, portal, hepatic and venous blood.

Authors:  J H Cummings; E W Pomare; W J Branch; C P Naylor; G T Macfarlane
Journal:  Gut       Date:  1987-10       Impact factor: 23.059

7.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

8.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases.

Authors:  Daniel N Frank; Allison L St Amand; Robert A Feldman; Edgar C Boedeker; Noam Harpaz; Norman R Pace
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-15       Impact factor: 11.205

9.  Diet drives quick changes in the metabolic activity and composition of human gut microbiota in a validated in vitro gut model.

Authors:  Marisol Aguirre; Anat Eck; Marjorie E Koenen; Paul H M Savelkoul; Andries E Budding; Koen Venema
Journal:  Res Microbiol       Date:  2015-10-24       Impact factor: 3.992

10.  Dysbiosis of the gut microbiota in disease.

Authors:  Simon Carding; Kristin Verbeke; Daniel T Vipond; Bernard M Corfe; Lauren J Owen
Journal:  Microb Ecol Health Dis       Date:  2015-02-02
View more
  1 in total

1.  Effects of Xylo-Oligosaccharide on the Gut Microbiota of Patients With Ulcerative Colitis in Clinical Remission.

Authors:  Zongwei Li; Zhengpeng Li; Liying Zhu; Ning Dai; Gang Sun; Lihua Peng; Xin Wang; Yunsheng Yang
Journal:  Front Nutr       Date:  2021-12-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.